Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report

Yan Liu, MD; XiaoMei Song, MD; LingYa Xiang, MD; Wei Tan, MD; Min Zou, MD; Hong Guo, MD

Current Therapeutic Research (Jan 2024)

Rapid Remission With Upadacitinib in a Child With Refractory Crohn's Disease and ATM Mutation: A Case Report

Yan Liu, MD,
XiaoMei Song, MD,
LingYa Xiang, MD,
Wei Tan, MD,
Min Zou, MD,
Hong Guo, MD

Affiliations

Yan Liu, MD: Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China
XiaoMei Song, MD: Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China
LingYa Xiang, MD: Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China
Wei Tan, MD: Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China
Min Zou, MD: Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China
Hong Guo, MD: Address correspondence to: Hong Guo, MD, Chongqing General Hospital, 118, Xingguang Avenue, Liangjiang New Area, Chongqing, 401147, China.; Department of Gastroenterology, Chongqing General Hospital, Chongqing University, Chongqing, China

Journal volume & issue: Vol. 101
p. 100756

Abstract

Read online

ABSTRACT: Managing pediatric Crohn's disease (PCD) presents challenges due to severe complications and higher biologic therapy needs. Transitioning from anti–tumor necrosis factor agents to off-label therapies adds complexity. Although upadacitinib has demonstrated efficacy and tolerability in adult inflammatory bowel disease and pediatric atopic dermatitis, there are limited data for its application in PCD. This case report delineates successful remission with upadacitinib in a child with CD refractory to infliximab, ustekinumab, adalimumab, thalidomide, and prednisone. Notably, the patient carried an ataxia telangiectasia mutated (ATM) gene mutation. These findings provide valuable evidence for PCD management and highlight the potential benefits of upadacitinib in this population.

Published in Current Therapeutic Research

ISSN: 0011-393X (Print); 1879-0313 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://www.journals.elsevier.com/current-therapeutic-research/

About the journal

Abstract

Keywords